Peer-reviewed veterinary case report
Vanguard C4 vaccine protects dogs against all CPV-2 variants
By Packianathan, Raj et al.·Published in Viral immunology·2022·Veterinary Medicine Research and Development, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Cross-Neutralization of Vanguard C4 Vaccine Against Australian Isolates of Canine Parvovirus Variants CPV-2a, CPV-2b, and CPV-2c.
- Species:
- dog
Plain-English summary
A study found that the Vanguard C4 vaccine effectively protects dogs against three variants of canine parvovirus (CPV-2a, CPV-2b, and CPV-2c), which are significant threats to dog health in Australia and worldwide. Researchers tested blood samples from vaccinated dogs and discovered that the vaccine successfully induced antibodies that can neutralize all three variants. This means that dogs receiving the Vanguard C4 vaccine are likely to have better protection against these dangerous viruses. If you're concerned about parvovirus and your dog's vaccination status, discussing the Vanguard C4 vaccine with your veterinarian could be beneficial.
People also search for: dog parvovirus vaccine · Vanguard C4 vaccine effectiveness · canine parvovirus variants · dog vaccination against parvovirus
Abstract
Canine parvovirus type 2 (CPV-2) remains one of the most significant viral pathogens in dogs in Australia and worldwide despite the availability of safe and effective CPV vaccines. At least three different variants of CPV-2 have emerged and spread all around the world, namely CPV-2a, CPV-2b, and CPV-2c. The ability of the current vaccines containing either original CPV-2 type or CPV-2b variant to cross protect the heterologous variants has been well demonstrated in laboratory studies, despite some concerns regarding the vaccine efficacy against the emerging variants. Vanguard, a series of multivalent vaccines, has been in the market for a considerable period of time and demonstrated to provide efficacy against all three types of CPV variants CPV-2a, CPV-2b, and CPV-2c. The purpose of this study was to evaluate the ability of the recently registered Vanguard C4 vaccine to induce cross-neutralizing antibodies against the Australian isolates of CPV-2a, CPV-2b, and CPV-2c variants. Blood samples collected from dogs vaccinated with Vanguard C4 were analyzed by virus neutralizing assays developed for each of three CPV variants. The results of the study demonstrated that Vanguard vaccine induced cross-neutralizing antibodies against the Australian isolates of CPV-2a, CPV-2b, and CPV-2c, thus offering cross protection against all three Australian CPV variants.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35997600/